Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma

• Main Authors: Nanumi Han (Author), Muhammad Baghdadi (Author), Kozo Ishikawa (Author), Hiraku Endo (Author), Takuto Kobayashi (Author), Haruka Wada (Author), Keisuke Imafuku (Author), Hiroo Hata (Author), Ken-ichiro Seino (Author)
• Format: Book
• Published: BMC, 2018-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 10.1186/s41232-018-0060-2; 1880-8190
• Keywords: Interleukin-34; Immunotherapy; Melanoma; Tumor-associated macrophage; Pathology; RB1-214
• Source: Inflammation and Regeneration, Vol 38, Iss 1, Pp 1-5 (2018)

Abstract Background Immunotherapies that target immune-checkpoint molecules such PD-1 have helped to achieve durable responses in melanoma treatment. However, 25% of melanoma patients who showed objective responses to PD-1 blockade develop resistance and suffer from disease progression and ultimately death, which necessitates the identification of related resistance mechanisms. IL-34 is a cytokine that controls the biology of myeloid cell lineage through binding to CSF-1R. IL-34 is importantly involved in the pathogenesis of various diseases. In cancer, the expression of IL-34 has been suggested to associate with tumor growth, metastasis, angiogenesis, and therapeutic resistance such as in lung cancers and malignant pleural mesotheliomas. In this study, we evaluate the possible involvement of IL-34 in immunotherapeutic resistance. Case presentation Melanoma resection species were obtained from a patient who developed a refractory melanoma against immunotherapy with Nivolumab, and stained with anti-IL-34, anti-melanoma antigens and anti-CD163 antibody. Staining of these markers was compared between primary or metastatic refractory melanoma tissues. Immunohistochemistry staining of melanoma tissues showed an enhanced expression of IL-34 in metastatic refractory melanoma compared to primary melanoma tissues, which correlates with increased frequencies of CD163+ macrophages. Conclusion We introduce for the first time a clinical case of a patient with metastatic refractory melanoma that acquired resistance to anti-PD-1 immunotherapy, showing an enhanced expression of IL-34 in refractory melanoma tissues.